Transplantation · 2010 · 157 citations · 30 references
MedicineImmunologyNephrologyKidney TransplantationRenal PathologyTransplant ImmunologyAcute RejectionAntibody-mediated RejectionDeceased Donor Kidney TransplantationDonor-specific AntibodiesImmunosuppression In Kidney TransplantationTransplant RejectionAntibody-mediated Rejection TherapyDonor-specific Antibody AssessmentDonor-specific Antibody ManagementGlomerular Filtration Rate AssessmentGlomerular Filtration Rate MeasurementHumoral RejectionPreexisting Donor-specific AntibodiesPreformed Donor-specific Antibodies
BACKGROUND: This study assesses the immunologic, functional, and histologic course of kidney recipients with preformed donor-specific alloantibodies (DSA) receiving deceased donor kidneys according to two prophylactic strategies that have been sequentially applied posttransplant. METHODS: The first strategy combined posttransplant quadritherapy/intravenous immunoglobulin (group 1, n=36) and the second added to the above protocol anti-CD20/plasmapheresis (group 2, n=18). All patients had a concomitant evaluation of glomerular filtration rate, protocol biopsies, and DSA mean intensity of fluorescence (MFI) at 3 month and 1 year posttransplant. RESULTS: Peak and day-0 class-I or II DSAmax-MFI were similar in both groups. The rate of acute antibody-mediated rejection (AMR) was similar in both groups (19.6% vs. 16.6%, respectively). At 1 year posttransplant, group 2 was characterized by lower microcirculation inflammation lesions (glomerulitis+capilaritis score of 1.8+/-0.2 vs. 2.7+/-0.2, respectively, P=0.03), a lower rate of transplant glomerulopathy (7% vs. 38%, P=0.02), and a lower rate of chronic AMR (41.3% vs. 13.3%, respectively, P=0.03). The decline in DSA-MFI from day 0 to 1 year was 44%+/-13% in group 1 compared with 80%+/-8% in group 2 (P=0.02). Finally, the 1-year glomerular filtration rate was 43+/-16 vs. 54+/-16 mL/min/1.73 m(2) in groups 1 and 2, respectively (P=0.04). CONCLUSION: This study raises the possibility that a more intensive day 0 prophylactic immunosuppressive strategy combining intravenous immunoglobulin/anti-CD20/plasmapheresis in this high-risk population, despite similar rates of early acute clinical humoral rejection, is associated with significant differences in long-term function and chronic AMR rate. Future prospective randomized studies are needed to assess the best strategies to be applied in light of the pretransplant immunologic risk stratification.
30
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text
Life Sciences, Immunology, Pathology +14
Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation
Daniel C. Brennan, John A. Daller, Kathleen D. Lake et al. · New England Journal of Medicine · 2006 · 730 citations · Full text
Medicine, Nephrology, Pharmacology +17